Senhwa Biosciences News and Activities
Presence
Headquarters: Taiwan
Senhwa Biosciences is a company listed under the stock ticker 6492 (TW).
Acquisition, funding and merger involving Senhwa Biosciences.
- Senhwa Biosciences has just announced a $500 Million fundraising (posted on April 16 2026).
Executives
View the org chart displaying its 8 main executives
Most searched biographies at Senhwa Biosciences
- Jason Huang, Acting Chief Executive Officer and Chief Medical Offi...
- Benny Hu, Chairman of the Board
- Daniel Mccormick, Director of Clinical Operations, US Office
Popular executive movements at Senhwa Biosciences
- Jenny Chen has joined the company as Director, Clinical Department (posted on November 10 2025).
- Taylor Hsu has joined the company as Business Development Director (posted on November 10 2025).
Create your alert
to follow the executive moves at Senhwa Biosciences.
Biotechnology
Senhwa Biosciences has 2,406 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and BioNTech (Germany).
Popular M&A news in Biotechnology
- Laboratoire Servier has announced the acquisition of Edgewise Therapeutics (posted on June 4 2026).
- Oak Hill Bio has just announced a $33 Million fundraising (posted on June 4 2026).
- IMU Biosciences has just announced a $53 Million fundraising (posted on June 3 2026).
Popular contacts in Biotechnology
News
Press releases by Senhwa Biosciences
- Senhwa Biosciences Launches Global Study, Targeting Breakthrough in Hard-to-Treat Cancers with CX-5461 and Tislelizumab Combination
- Senhwa Biosciences Secures Strategic Backing from Global Investor GEM with Up to NT$500 Million to Accelerate AI-Driven Drug Development
- Breakthrough at 2026 AACR! Senhwa Biosciences’ CX-5461 Enters the Field of Photodynamic Therapy, Opening a New Indication Strategy
- Senhwa Biosciences Signs Major Strategic MOU with Y Combinator-Backed AI Biotech Company CellType to Accelerate the Evolution of CX-4945 into Version 2.0 and Reshape the Global Immunotherapy Landscape
- Senhwa Biosciences Aims at Multi-Billion Dollar Global Market with CX-5461 Combined with ADC “Blockbuster” Therapy
- Senhwa Biosciences Highlights AI-Validated Oncology Platform and Strategic Clinical Collaborations Targeting Next-Generation Immuno-Oncology products at Its 2025 Annual Investor Conference
- Senhwa Biosciences and BeOne Medicines Announces a Clinical Supply Agreement to Address the Challenge of Cold Tumors-BeOne
- Google AI Breakthrough Highlights Silmitasertib (CX-4945) as a Novel Pathway in Cancer Immunotherapy
- Senhwa Biosciences’ CX-5461 Teams Up with Global PD-1 Leaders to Enter the Immunotherapy Arena, Targeting Multi-Billion Dollar Global Market
- Senhwa Biosciences CX-5461 Secures NCI Support to Advance into MYC-Driven Lymphoma, Driving Cross-Cancer and Global Licensing Value
- View more press releases Close
Social media about Senhwa Biosciences
- Senhwa Biosciences on Wikipedia, Google News & Yahoo Finance
- Senhwa Biosciences on LinkedIn, X (Twitter) & YouTube
